---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026351"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:22:51.649405+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Beth Seidenberg resigns; shareholders reject officer exculpation amendment at annual meeting

## Summary
- Director Beth Seidenberg resigned from Board effective June 1, 2023, to pursue other activities.
- Board reduced from eight to seven directors.
- At annual meeting, stockholders elected Pascal Touchon, Carol Gallagher, and Maria Grazia Roncarolo as directors.
- Advisory vote on executive compensation approved (71.8M for, 2.2M against).
- Proposal to amend Certificate of Incorporation to exculpate officers was not approved (38.6M for, 35.4M against).

## SEC filing metadata
- accession: 0000950170-23-026351
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/atra-20230531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026351
- JSON: https://secwatch.observer/filing/0000950170-23-026351.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026351.txt

## Key facts
- Executive change
  Beth Seidenberg resigned as Director at Atara Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On June 1, 2023, Beth Seidenberg, M.D., notified Atara Biotherapeutics, Inc. (the “ Company ”), of her resignation from the Board of Directors of the Company (the “ Board ”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm
- Shareholder Votes
  Atara Biotherapeutics, Inc. shareholders approved Election of Directors at the 2023-05-31 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: Each of the three nominees for director was elected to serve until the 2026 annual meeting of stockholders and until their respective successors are elected.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm
- Shareholder Votes
  Atara Biotherapeutics, Inc. shareholders approved Advisory vote to approve on the compensation of the Company’s named executive officers at the 2023-05-31 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm
- Shareholder Votes
  Atara Biotherapeutics, Inc. shareholders rejected Approval of an amendment to Company’s Certificate of Incorporation at the 2023-05-31 meeting.
  - Proposal: charter amendment
  - Outcome: failed
  - Meeting: 2023-05-31
  source text: The stockholders did not approve an amendment of the Company’s Certificate of Incorporation to provide for the exculpation of officers as permitted by Delaware law.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm
- Shareholder Votes
  Atara Biotherapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2023-05-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023026351/0000950170-23-026351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.